pre-IPO PHARMA

COMPANY OVERVIEW

Immunocore is the world’s leading T cell receptor (TCR) company, a global biotech striving to transform medical practice in the most challenging disease areas. The Company is focused on delivering first-in-class biological therapies to patients, using its highly innovative soluble TCR platform, and ImmTAC® molecules, a new class of precision-engineered drugs with ultra-high affinity for intracellular cancer targets. ImmTAC molecules naturally recognise cancer cells and cause their destruction through re-directing and activating the patient’s own immune system. This novel class of immunotherapy has the potential to treat a broad spectrum of diseases with high unmet medical need, not only cancers, but also infectious diseases and autoimmune diseases.


LOCATION

  • Milton, Abingdon, UK
  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Infectious Disease
  • Oncology

  • WEBSITE

    https://www.immunocore.com


    CAREER WEBSITE

    https://www.immunocore.com/career


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Feb 10, 2021

    Citi Appointed as Depositary Bank for Immunocore Holdings plc’s ADR Programme


    Dec 9, 2019

    Immunocore announces dosing of first patient with third ImmTAC bispecific


    Oct 31, 2019

    Immunocore to Spotlight ImmTAC Platform Research at 2019 SITC Annual Conference


    Oct 31, 2019

    Immunocore to Spotlight ImmTAC Platform Research at 2019 SITC Annual Conference


    Jul 18, 2019

    Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma


    For More Press Releases


    Google Analytics Alternative